
Fibronostics and Stone Diagnostics Partner to Advance Non-Invasive Liver Disease Assessment
Fibronostics, a laboratory focused on AI-powered, non-invasive diagnostic testing for patients with Metabolic Associated Fatty Liver Disease (MAFLD) and Metabolic Associated Steatohepatitis (MASH), has announced a new partnership with Stone Diagnostics, a laboratory services provider in the United States. Stone currently operates two regional laboratories in New Orleans and the Florida panhandle. Under the terms of the agreement, Stone Diagnostics will provide Physicians and their patients access to LIVERFASt™ through their laboratory network and provide access to their digital tools and services.
LIVERFASt™ is a proprietary diagnostic test that measures 10 biomarkers associated with liver disease and fibrosis. It seeks to detect metabolic diseases such as metabolic associated fatty liver disease and metabolic dysfunction-associated steatohepatitis to allow for early intervention and treatment. About 25% of adults have abnormal fat build up in the liver and untreated it can lead to serious health risks such as liver damage and cirrhosis. Disease diagnosis is typically done following abnormal blood tests for liver function, or through ultrasound or in some cases liver biopsy.
Brock Smith, Fibronostics GM for the Americas, underscored the strategic significance of the partnership, explaining, “Our strategic partnership with Stone Diagnostics gives us the comprehensive, efficient, reproducible, and scalable Laboratory Operations Platform required to meet increasing LIVERFASt™ demand and allows us to focus on the most important needs of our Prescribers and their Patients. Our mission is to deliver Best-In-Class AI-driven Medical Technology and Customer Support to our Customers and their Patients, and this partnership with Stone will position us to do just that.”